Capecitabine-based approach shows promise in a population with few options
Focus is on inhibiting action of myeloid-derived suppressor cells
Understanding the role of patient sex may lead to personalized therapies
Rationale and status reports on mechanistically diverse strategies
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy